James Sullivan, MD
Internal Medicine · Birmingham, ALNPI 1588613020
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Indivior Inc. at 33.5% of the total. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $34.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$13K
- Novo Nordisk$6K
- Amgen$4K
- AstraZeneca$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- plus $11K from 54 others
Across 45 payments — averaging $134,010 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.8M
- Eli Lilly$1.7M
- Astrazeneca UK Limited$1.2M
- Novartis$398K
- AbbVie$16K
- Orexo US, Inc.$4K
What the payments were for
- Consulting fees$3,5789%
- Speaking & faculty fees$12,05031%
- Travel & lodging$3,92210%
- Food & beverage$19,38350%
- Education$1390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,071 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 2,431 | $546,282 |
| MounjaroTirzepatide | 353 | $481,672 |
| OzempicSemaglutide | 374 | $473,570 |
| EliquisApixaban | 531 | $371,971 |
| LinzessLinaclotide | 326 | $269,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 280 | $249,501 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 220 | $198,796 |
| JardianceEmpagliflozin | 165 | $166,363 |
| RexultiBrexpiprazole | 106 | $166,128 |
| TrulicityDulaglutide | 102 | $130,442 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 180 | $112,935 |
| Humira PenAdalimumab | 14 | $97,413 |
| FarxigaDapagliflozin Propanediol | 72 | $70,813 |
| RybelsusSemaglutide | 64 | $70,605 |
| XareltoRivaroxaban | 72 | $70,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,359 | $612,113455 claims |
| Novo NordiskOzempic, Rybelsus | $6,261 | $544,175438 claims |
| PfizerEliquis, Nurtec Odt | $985 | $433,484584 claims |
| AbbVieLinzess, Creon, Vraylar | $1,097 | $352,633367 claims |
| GSKTrelegy Ellipta | $971 | $249,501280 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $276 | $198,796220 claims |
| Indivior Inc.Suboxone, Sublocade | $13,092 | $173,629210 claims |
| Boehringer IngelheimJardiance | $622 | $166,363165 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $467 | $166,128106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,996 | $126,838152 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $637 | $111,080105 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $52,34471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- Ryan WeldonBirmingham$458K
- Robert LewisBirmingham$187K
- Thomas HuddleBirmingham$76K
- Jose VargasBirmingham$49K
- Donna FicoBirmingham$46K
- Ross SchumacherBirmingham$26K
- Larry AlfordBirmingham$25K
- David WynneBirmingham$22K
- James CrenshawBirmingham$16K
- David WilhelmBirmingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.